You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
A股異動丨濟川藥業大跌逾9% 前三季度營收和利潤雙降 蒲地藍銷量承壓
格隆匯 10-28 10:18
格隆匯10月28日丨濟川藥業(600566.SH)大跌逾9%,報25.29元,成交2.3億元,總市值206億元。

濟川藥業上週五晚間發佈2019年第三季度報告:2019年初至報告期末:營業收入為5,385,992,915.70元,比上年同期下滑2.85%;歸屬於上市公司股東的淨利潤為1,305,562,344.39元,比上年同期下滑0.24%。據瞭解,報告期內營業外收入比上年同期下滑59.68%,主要系報告期內計入營業外收入的政府補助減少所致。濟川藥業旗下拳頭產品蒲地藍的銷售承壓在報告期充分體現。此前,國家藥監局對蒲地藍消炎製劑統一修訂説明書,在不良反應、禁忌、注意事項方面做了明確説明,尤其是明確了“孕婦慎用”。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account